The GIRFT Thrombosis Survey was launched on 1st October 2019 and was originally planned to run until 31st March 2020.
The deadline for Part 3 (HAT) data entry has now been extended to August 31st 2020 to help capture data around the link between increased venous thrombosis associated with COVID-19.
No further data for Part 1 (organisational) or Part 2 (VTE prevention) is required, but participants are asked to complete the data for hospital-acquired thrombosis (HAT) for the additional months of April and May, to allow for figures seen during the peak of COVID activity. A new COVID tab has been added to the portal.
The GIRFT Thrombosis Survey is co-badged by the Royal College of Surgeons and the Royal College of Physicians, and supported by the National VTE (venous thromboembolism) Exemplar Centres Network in collaboration with Thrombosis UK.
The purpose of the survey is to:
- Identify the number of cases of HAT (Hospital Acquired Thrombosis) in a six-month period (now extended by two months).
- Identify the clinical areas where HAT occurs, identifying whether HAT has occurred after medical or surgical admission and the type of surgical admission.
- Determine the proportion of HAT cases which are deemed potentially preventable.
- Identify common themes within cases of potentially preventable HAT.
- Assess local practice in the prevention of HAT.
- Provide data for participating trusts or hospitals, to benchmark themselves against the national average and to drive better scrutiny and investigation of HAT and their causes.
The survey questions have been developed by professor of thrombosis Professor Roopen Arya and consultant haematologist Dr Lara Roberts – both of King’s College Hospital NHS Foundation Trust, London – in consultation with Thrombosis UK, and have been reviewed by a panel of experts from professional bodies.
This survey offers a unique opportunity to capture data on the increase in COVID-related thrombosis nationally. It is thought that 30% of patients who fall severely ill with COVID-19 develop thrombosis, which may contribute to death rates.
For further information on the survey, contact GIRFT project manager Anne-Marie Ridgeon at [email protected]